Novox

Quick links to important sections

Novox

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novox

What is Novox? Overview and Quick Facts

Property Description
Active ingredient Carprofen
Form Oral tablet, often chewable
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
General purpose Anti-inflammatory and analgesic relief
Origin Synthetic propionic acid derivative

What is Novox and its Active Ingredient?

Novox is a trade name for the active compound Carprofen, a pharmaceutical agent classified as a Non-steroidal Anti-inflammatory Drug (NSAID). This synthetic substance is derived from propionic acid, a chemical classification it shares with other established NSAIDs. Novox is designated as a veterinary medicine approved for use exclusively in canines. This regulatory status establishes that the medication is specifically intended for dogs.

Carprofen's identity is rooted in its action as an NSAID, a class of medication known for exhibiting both analgesic (pain-relieving) and antipyretic (fever-reducing) characteristics. Its targeted pharmacological mechanism is used for the management of discomfort associated with various canine conditions. Clinical observations confirm that the primary function of Carprofen is to mitigate pain and control inflammation in the canine patient population.

Novox Composition, Form, and General Purpose

Novox is a single-ingredient product supplied as an oral formulation in the form of tablets, which are often offered as chewable tablets to simplify the administration process, a feature utilized in veterinary practice. The core composition includes the Carprofen active ingredient combined with pharmaceutical excipients necessary to ensure a stable, accurately dosed unit for the oral route of administration.

The general purpose of this medication is to provide anti-inflammatory and analgesic relief by inhibiting the production of inflammatory mediators in the body. Carprofen achieves this through the selective modulation of the cyclooxygenase (COX) enzyme system. This fundamental action supports the general benefit of mitigating patient discomfort, relieving stiffness, and promoting improved mobility.

Regulatory References

  1. U.S. Food and Drug Administration (FDA)
  2. FDA Approval

What side effects are possible with Novox?

Possible Side Effects and Safety Information

The safety profile of Novox (Carprofen), a non-steroidal anti-inflammatory drug (NSAID), is documented by regulatory bodies such as the FDA and EMA. Adverse reactions are classified by frequency and the physiological system affected.


System-Organ Classes and Reported Effects

The most frequently reported side effects are categorized as Gastrointestinal Disorders, including vomiting, diarrhea, soft stool, and anorexia (loss of appetite). Other involved system-organ classes are Hepato-biliary Disorders, Renal and Urinary Disorders, and Nervous System Disorders.

Adverse Reaction Category Examples of Officially Documented Effects
Gastrointestinal (Most Frequent) Vomiting, diarrhea, anorexia, GI ulceration/perforation
Systemic/General Lethargy, increased thirst (polydipsia)
Hepatic (Rare but Serious) Elevated liver enzymes, acute hepatic toxicity/failure
Renal (Rare but Serious) Acute renal failure, kidney dysfunction

Serious Reactions and Safety Constraints

Although rare, officially documented Serious Adverse Reactions include Gastrointestinal Ulceration and Perforation, as well as Acute Hepatic and Renal Failure. These are explicitly highlighted in regulatory safety documents.

Use is subject to specific constraints documented in the product labeling. The medication is contraindicated in animals with known hypersensitivity to Carprofen and should be avoided in those with pre-existing conditions such as renal, hepatic, or cardiac disease, or a history of GI ulceration. Adverse reactions are most often noted during the initial days of treatment and are generally reversible upon cessation.

Population-Specific Safety: Novox is not for use in pregnant or lactating animals, puppies under four months old, or dehydrated animals due to increased risk of toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe that an overdosage of Novox (Carprofen) may result in severe manifestations across several physiological systems. Documented signs may include serious gastrointestinal effects such as vomiting, diarrhea, melena (black, tarry stools), and hematemesis (vomiting blood). Furthermore, systemic toxicity may present with neurologic effects, including ataxia, disorientation, paresis, seizures, and paralysis. Laboratory findings often show signs of toxicity through azotemia and elevated hepatic enzymes.

Overdosage carries the potential for severe, life-threatening outcomes, including acute renal failure and acute hepatic toxicity, in addition to the risk of gastrointestinal perforation secondary to ulceration. Patients with pre-existing renal, hepatic, or cardiovascular dysfunction, as well as elderly patients, are noted in the official labeling as involving additional risk. Management for overdosage is defined as general supportive therapy and symptomatic treatment, as regulatory information confirms that no specific antidote is known.

Regulator-mandated emergency actions require that if consumption above the labeled dose is suspected, the owner must contact a veterinarian immediately. If serious clinical signs of toxicity are observed, the administration of the medication must be stopped, and immediate medical attention is required.

Therapeutic Uses of Novox

What Novox Treats: Main Uses and Benefits

Novox (Carprofen) is a veterinary Non-steroidal Anti-inflammatory Drug (NSAID) used exclusively in canines, primarily to provide analgesic and anti-inflammatory support. The medication is commonly used to help with the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative discomfort following soft tissue and orthopedic procedures.


Understanding the Therapeutic Scope

This medicine is applied across domains where additional symptomatic support is needed, addressing conditions characterized by chronic joint disease and acute injury-related discomfort. It helps address symptom clusters that may become intense or disruptive, such as lameness, a limping gait, and stiffness upon rising.

The overall benefit contributes to improved day-to-day comfort and the maintenance of stability. The use of Novox may assist with maintaining functional stability and better weight-bearing ability during symptomatic periods. This medication is relevant because:

“It is commonly used to help manage the persistent symptoms related to physical discomfort and stiffness.”


Key Therapeutic Contexts

Novox is particularly relevant in clinical settings that involve acute or disruptive symptom patterns, and it is also utilized for the long-term, supportive management of conditions like Degenerative Joint Disease (DJD). It plays a role in managing episodes where symptoms escalate temporarily, such as during the immediate recovery phase following surgery.

Quick Fact: Supportive Management for Pain and Inflammation
Primary Focus Musculoskeletal pain and joint inflammation
Common Scenarios Long-term management of OA; short-term postoperative use
Symptom Easing Stiffness, limping, and associated joint discomfort

Regulatory References

  1. U.S. Food and Drug Administration (FDA) Freedom of Information Summary

Eligibility and Restrictions for Use

Novox (Carprofen) is a veterinary Non-steroidal Anti-inflammatory Drug (NSAID) whose eligibility is strictly defined by government regulatory agencies. The medicine is approved only for use in canines (dogs) 6 weeks of age and older. The labeling establishes clear boundaries on who can and cannot use the medicine.


Absolute Exclusions and Contraindications

Use of the medicine is contraindicated and must not occur in dogs with a known hypersensitivity to carprofen. Due to species-specific differences, the product is explicitly prohibited for use in Cats (Felines) and is Not for human use.


Restricted and Not Established Use

Population Group Eligibility Status Defined by Regulators
Age Use Not Established in animals less than 6 weeks of age.
Reproductive Status Use Not Established in pregnant dogs, lactating bitches, or dogs used for breeding.
Coagulation Not Recommended in dogs with bleeding disorders due to lack of established safety.
High-Risk Organ Status Caution Required in dogs with existing renal, hepatic, or cardiovascular dysfunction or dehydration, as these animals are at greatest risk for toxicity.

The official profile classifies these restrictions to guide appropriate use, utilizing formal statuses such as contraindicated, not recommended, and use not established.

What should I know about interactions with other medicines?

Novox (Carprofen) interaction patterns are documented in regulatory information primarily as pharmacodynamic risks and mandatory prohibitions concerning co-administration. These restrictions relate to additive toxicity and pharmacokinetic displacement.

Classification Restriction or Effect
Contraindicated Combinations Co-administration with other NSAIDs or glucocorticoids (corticosteroids) is officially prohibited. This prohibition is due to the documented increase in risk for severe adverse effects, specifically gastrointestinal ulceration and/or perforation.
Timing Restriction Novox must not be administered concurrently with other NSAIDs or glucocorticoids, or within 24 hours of their administration.
Cardio-Renal Agents Co-administration with diuretics (e.g., Furosemide) or ACE inhibitors may reduce the intended efficacy of these agents and increase the potential risk of renal toxicity.
Bleeding Risk Concomitant use with anticoagulants requires cautious monitoring due to a documented potential for an increased risk of bleeding.
Exposure Modification Novox is highly bound to plasma proteins. Co-administration with other highly protein-bound medicines may result in a transient increase in the unbound plasma concentration of either substance through competition for binding sites.
Food Interaction Administration with food is noted in regulatory documents as a method to potentially reduce gastrointestinal upset.

The official regulatory profile is structured by mandatory prohibitions for other anti-inflammatory drugs and further highlights necessary caution for combinations that interfere with renal function. The documentation defines these interactions by their additive risk and effects on other medicines.

Mechanism of Action

How Novox Selectively Inhibits the COX-2 Enzyme

Novox acts as a selective competitive inhibitor that physically blocks the active site of the Cyclooxygenase-2 (COX-2) enzyme

. This targeted action is the initial molecular step that prevents the conversion of its substrate, arachidonic acid, thereby interrupting the Eicosanoid signaling cascade. By inhibiting COX-2, Novox effectively suppresses the synthesis of pro-inflammatory prostaglandins (e.g., PGE2), which are chemical mediators produced rapidly at sites of tissue distress. Modifying these early molecular steps functions to restrict the downstream consequences of elevated mediator activity.

Physiological Consequence of Reduced Mediator Levels

The reduced concentration of these mediators contributes to the dampening of heightened physiological activity within the peripheral and central pathways responsible for nociception and thermoregulation. This mechanism ultimately results in the predictable physiological adjustments of attenuated transmission of noxious stimuli and the normalization of the hypothalamic set-point for body temperature.

Dosage and Administration Information

How Novox is Used: Official Dosing and Administration

Novox (carprofen) is a veterinary non-steroidal anti-inflammatory drug (NSAID) prescribed for oral use only in dogs. Proper usage is defined by specific guidelines to ensure correct administration. The medication is available as scored caplets and chewable tablets in 25 mg, 75 mg, and 100 mg strengths.


Standard Dosing Regimen

The recommended total daily dose is calculated based on the dog's weight, and the protocol is to use the lowest effective dose for the shortest duration necessary. The official dose is:

2 mg per pound (4.4 mg/kg) of body weight daily

This total daily dose can be administered in one of two ways, providing flexibility in the dosing schedule:

Administration Schedule Dose per Administration Frequency
Option 1 (Once Daily) 2 mg/lb (4.4 mg/kg) Once Daily (q24h)
Option 2 (Divided Daily) 1 mg/lb (2.2 mg/kg) Twice Daily (q12h)

Administration Conditions and Restrictions

Standard parameters provide specific practical details for proper use:

  • Intake: Novox tablets may be given with or without food. They can be offered by hand, mixed with food, or administered directly.
  • Tablet Splitting: The tablets are scored, allowing for half-tablet increments to ensure accurate, weight-based dosing.
  • Use Limitations: The medication is strictly for dogs only and must not be used in cats. Safety has not been established in animals less than 6 weeks of age or in pregnant/breeding dogs, establishing key age and reproductive constraints on its use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Novox

This overview describes the types of research and clinical studies that have been conducted on Novox (Carprofen) and what those studies examined, focusing on evidence reviewed by regulatory bodies. This summary is intended to provide context on the available research and is not a guide for treatment or use.


Evidence for Use in Osteoarthritis (OA) and Degenerative Joint Disease (DJD)

Research for conditions characterized by functional limitations, such as Osteoarthritis (OA) and Degenerative Joint Disease (DJD), includes randomized controlled trials (RCTs) and long-term observational studies. These studies were applied to client-owned canines diagnosed with naturally occurring joint disease. Researchers monitored outcomes related to physical discomfort and daily functioning.

The studies primarily monitored functional metrics, such as lameness (limping) and weight-bearing ability. They also used owner and veterinarian assessments to monitor mobility scores and stiffness upon rising. Findings describe patterns measured during the study period where assessments of movement and comfort were tracked in the observed populations. These results reflect the specific conditions under which they were conducted.

Evidence for Use in Controlling Postoperative Discomfort

Studies explored the immediate recovery period following surgery. Studies were primarily short-term, randomized, comparative clinical trials involving canines undergoing common surgical procedures, including both soft tissue and orthopedic operations.

The studies monitored outcomes describing episodic or acute changes in pain. Researchers examined symptom intensity and variability using validated pain assessment tools. Research describes patterns related to the rate of rescue analgesia use observed in the study groups compared to control groups in the immediate 24-to-72-hour period. Studies report how symptoms evolved in the observed populations over these defined time intervals.

Evidence Gaps and Areas of Scientific Uncertainty

Limited data are available concerning long-term structural effects on joint cartilage or bone from the available clinical trials. Comparative evidence is lacking against every potential alternative treatment, and not all trials used contemporary non-inferiority designs. Furthermore, sample sizes in some studies were modest, and the evidence quality varies across studies, which can affect the certainty of findings. The research provides context on patterns observed in the studies so far, but it does not determine whether an individual will respond similarly.

Key Studies & References

  1. U.S. Food and Drug Administration (FDA) Freedom of Information Summary for Novox (Carprofen)
  2. Randomized controlled trials and meta-analyses on Carprofen for pain and inflammation in dogs with osteoarthritis (Representative Peer-Reviewed Literature)
  3. Scientific reviews on Carprofen use for postoperative pain management in canines (Representative Peer-Reviewed Literature)

Frequently Asked Questions (FAQ)

Common questions about Novox (FAQ)


Q: How long does it usually take for a person to notice the effects of Novox?

Official information indicates that the medication is intended to help the animal patient feel better within approximately one to two hours after administration. Official information describes that clinical signs of improvement may be tracked shortly after this initial time frame. The full benefits are typically tracked over the course of treatment.


Q: Is Novox the same as [Name of common alternative drug]?

Novox contains the active ingredient Carprofen, which is classified as a Non-steroidal Anti-inflammatory Drug (NSAID). While it shares a drug class with many other commonly known medications, Carprofen itself is a distinct chemical compound evaluated and approved for use specifically in dogs.


Q: Is it necessary to take Novox every day, even when feeling better?

Regulatory labeling states that this medicine should be used for the shortest duration necessary to achieve the treatment goals defined by the veterinarian. This approach helps ensure the use is consistent with the patient's condition and individual response.


Q: Does Novox interact with common over-the-counter cold medicines?

Official documents prohibit the co-administration of Novox with other NSAIDs and certain hormone-based drugs called glucocorticoids (corticosteroids). Many human cold and pain relief medicines contain active ingredients from these forbidden classes. Co-administration with these classes may increase the documented potential risk for severe adverse effects.


Q: Does Novox tend to cause weight changes in people who take it long-term?

Novox is strictly a veterinary medicine, and regulatory studies focused on canines. Scientific studies reviewed by regulatory bodies describe that no clinically significant changes in the body weight of dogs receiving carprofen were observed in long-term controlled trials.


Q: Why do I see different strengths of Novox mentioned online?

The medication is approved in several strengths, including 25 mg, 75 mg, and 100 mg caplets and chewable tablets. The available strengths are intended to allow for accurate, weight-based administration as determined by a veterinarian.


Q: What happens if a person takes too much Novox by mistake?

Official labeling explicitly warns that Novox is Not for human use and must be kept strictly out of the sight and reach of children and pets. In the event of accidental human ingestion, official guidance is to immediately contact a physician or poison control center.


Q: Is the effectiveness of Novox dependent on a person's diet or lifestyle?

Official regulatory documents note that Novox tablets may be given with or without food. There is no official information to suggest that the medication's overall effectiveness depends on generalized diet or lifestyle factors beyond the administration instructions.


Q: Does taking Novox at a specific time of day make a difference?

The official dosing instructions allow for flexibility in the administration schedule. The total daily amount can be administered as a single dose once daily, or it can be divided into two smaller doses given twice daily (every 12 hours).


Q: Are skin reactions like rashes common side effects of Novox?

Official adverse event reporting from clinical field studies includes documented observations of dermatitis, which refers to general skin reactions. Monitoring the patient for any new skin or coat changes during administration is generally recommended.


Q: Does Novox interfere with birth control pills?

Novox is highly protein-bound, meaning it may compete for binding sites with other highly protein-bound medications, which can lead to increased concentrations of either substance in the bloodstream. Safety has also Not Been Established in pregnant or breeding animals. This general information provides context for potential drug interactions.


Q: How long does Novox stay in the system after the last dose?

Pharmacokinetic data available in authoritative sources indicate that the elimination half-life of Carprofen in dogs is approximately 8 hours (ranging from 4.5 to 9.8 hours). The half-life describes the time required for the amount of drug in the body to be reduced by half.


Q: Are there any tests needed before starting Novox therapy?

Official labeling states that appropriate laboratory tests to establish hematological (blood) and serum biochemical baseline data should be considered prior to, and periodically during, the administration of any Non-steroidal Anti-inflammatory Drug (NSAID).


Q: What does the patient information leaflet say about stopping Novox?

Patient information directs owners to contact a veterinarian immediately and note that cessation of the drug is generally indicated if they observe signs of potential drug toxicity or serious adverse reactions. Adverse reactions are often noted as reversible upon cessation.


Q: Is Novox a controlled substance?

Regulatory status for Carprofen is documented as prescription-only (Rx-only) in the U.S. and E.U. However, it is not classified as a federally controlled substance (e.g., Schedule I-V) in these regions.


Q: Has Novox been approved for use in children?

The medication is strictly for veterinary use in dogs only and has been evaluated and approved by regulatory bodies, such as the FDA, exclusively for use in canines 6 weeks of age and older. It is not approved for human use.


Q: Is it common to experience dizziness when first starting Novox?

Official adverse event reporting includes potential effects on the Nervous System, such as incoordination or disorientation. However, dizziness is not listed as a common or specific effect reported in the official safety documents.


Q: What are the official guidelines regarding drinking alcohol while on Novox?

Novox is strictly a medicine for dogs, making the consumption of alcohol by the patient entirely not applicable. Furthermore, alcohol is widely known to be highly toxic and dangerous for canines.


Q: Does Novox have any known effects on mental health or mood?

Official information mentions documented observations of general behavior changes in clinical field studies in dogs. These changes may include either increased or decreased activity level, or other changes in temperament.

How should Novox be stored and disposed of?

How to Store and Dispose of Novox?

Novox (carprofen) tablets must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F), with protection from both light and moisture. The product must be kept in its original container and maintained tightly closed.


The label strictly requires that the medication be stored out of the sight and reach of children and pets to prevent accidental ingestion. Any half-tablets that have been split must be used within 30 days.

Disposal of unused or expired Novox must be done according to local regulations. The product should not be disposed of via wastewater to minimize environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Novox found in:

A-Z Index: